Transgenic mouse models for tumors of melanocytes and retinal pigment epithelium

Détails

ID Serval
serval:BIB_FE1DD5022EF7
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Transgenic mouse models for tumors of melanocytes and retinal pigment epithelium
Périodique
Pigment Cell Research
Auteur⸱e⸱s
Beermann  F., Hunziker  A., Foletti  A.
ISSN
0893-5785
Statut éditorial
Publié
Date de publication
04/1999
Peer-reviewed
Oui
Volume
12
Numéro
2
Pages
71-80
Notes
Journal Article
Research Support, Non-U.S. Gov't
Review --- Old month value: Apr
Résumé
Cutaneous and ocular melanomas are due to malignant transformation of neural crest-derived melanocytes. The rising incidence of this tumor in humans has stimulated experiments to devise suitable mouse models. In the past years, transgenic mouse lines have been generated using different oncogenes - Ha-ras, SV40 T antigen (Tag), ret - which develop benign lesions of melanocytes, melanoma, and/or eye tumors. Pigment cell tumors in humans, although rather rare, can also develop from the retinal pigment epithelium (RPE), a cell layer of neuroectodermal origin. We, therefore, established transgenic models for this ocular tumor. Regulated by the promoter of tyrosinase-related protein-1 (TRP-1), two oncogenes, ret and SV40 Tag, were targeted to the developing RPE in transgenic mice. The TRP-1/ret transgenic mice displayed microphthalmia and benign tumors of the RPE. Expression of SV40 T antigen (TRP-1/Tag) led to malignant tumors, which were invasive and metastasized to inguinal lymph node and spleen.
Mots-clé
Animals Disease Models, Animal Humans *Melanocytes *Melanoma/genetics/physiopathology Mice *Mice, Transgenic *Pigment Epithelium of Eye *Retinal Neoplasms/genetics/physiopathology
Pubmed
Web of science
Création de la notice
17/01/2008 17:06
Dernière modification de la notice
20/08/2019 17:28
Données d'usage